## Gavi, the Vaccine Alliance Strategy 2021–2025 (updated version for 2023–2025)

Gavi (\*\*)

## Leaving no one behind with immunisation

**SUSTAINABLE DEVELOPMENT** 

Mission

To save lives and protect people's health by increasing equitable and sustainable use of vaccines

- Under-five child mortality reduced
- Future deaths averted
- Future DALYs averted

-10% 7-8m

320-380m

Reduction in zero-dose children (equity indicator)

Unique children immunised

Economic benefits unlocked

-25% 300m

US\$80-100bn

**Principles** 

 Missed communities. first priority

PCV3, HPVC

benchmark vaccines

preventive campaign

including through stockpiles

- Gender-focused
- Country-led, sustainable
- Community-owned
- Differentiated

Integrated

to immunisation

- Adaptive, resilient
- Innovative
- Collaborative, accountable

Goals

INTRODUCE AND SCALE UP **VACCINES** 



STRENGTHEN HEALTH SYSTEMS TO **INCREASE EQUITY IN IMMUNISATION** 

to regularly reach under-immunised



**IMPROVE SUSTAINABILITY OF IMMUNISATION PROGRAMMES** 



**ENSURE HEALTHY MARKETS FOR** 



В

Strengthen countries' prioritisation of vaccines appropriate to their context

Support countries to introduce and scale up

Breadth of protection: % average coverage

Vaccine coverage (SDG indicator 3.b.1):

epidemic and pandemic diseases

across key Gavi-supported vaccines

• Country Prioritisation: % of vaccine applications that demonstrate use of evidence to support prioritisation of vaccines appropriate to their context

coverage of vaccines for prevention of endemic,

% of target populations covered by DTP3, MCV2,

• Rate of scale-up of new vaccines: % coverage

of PCV3, rotavirusC, MCV2, and yellow fever

vaccines following introduction relative to

Vaccine introductions: # of introductions of

previously unvaccinated against measles who received an MCV dose in a Gavi-supported

Enhance outbreak and pandemic response

Ebola, measles, meningitis and yellow fever

outbreaks detected and responded to in

by ensuring equitable access to relevant vaccines

Outbreak detection and response: % of cholera,

Gavi-supported vaccines into routine immunisation

• Measles campaign reach: % of children under 5



% unweighted DTP3 coverage in 20% of districts with lowest coverage in each country

Help countries extend immunisation services

- DTP drop-out: drop-out rate between first and third doses of DTP-containing vaccine
- MCV1 coverage: % coverage of MCV1



for immunisation and primary health care to improve allocative efficiency

Strengthen national and subnational

political and social commitment

· Co-financing fulfilment (measure of 3a & 3b):

% of countries meeting co-financing commitments

Support countries to ensure **immunisation** services are resilient, well-managed, sustainable, harness innovation and meet the needs of all caregivers

- Immunisation sessions: # of immunisation sessions conducted in Gavi-supported countries
- Stock availability at facility level: % of Gavi-supported countries with no stock-outs of DTP- and measles-containing vaccines
- EPI management capacity: average of country composite scores for EPI programme management and coordination



Work with countries and communities to build resilient **demand**, and to identify and address **gender-related barriers** to immunisation

- **Demand:** % of countries implementing plans to overcome demand-related barriers to immunisation
- Gender: % of countries addressing gender-related barriers to immunisation



Promote domestic public resources



Prepare and engage self-financing countries to maintain or increase performance

- · Preventing backsliding in transitioned countries: # of former Gavi-eligible countries eligible for support under the Middle-Income Countries (MICs) Approach maintaining or increasing DTP3 coverage
- Vaccine introductions in MICs: # of PCV, rotavirus and HPV vaccine introductions in former and never Gavi-eligible countries currently eligible for support under the MICs Approach



VACCINES AND RELATED PRODUCTS



Ensure sustainable, healthy markets with diversified supply for vaccines and immunisation-related products at affordable prices

• Healthy market dynamics: # of markets exhibiting sufficient levels of healthy market dynamics



Incentivise **innovations** for the development of suitable vaccines

• Incentivise innovations: # of innovative products within the pipeline of commercial-scale manufacturers



Scale up **innovative** immunisation-related products

• Scale up innovation: # of vaccines and immunisation-related products with improved characteristics procured by Gavi

a timely manner